We interviewed 3 KOLs in the 7 days following the CheckMate-026 shake-up to find out how it will impact NSCLC treatment. Disappointing CheckMate-026 trial results may have sidelined Opdivo, creating a huge opportunity for rival Keytruda, and other immunotherapies.
Can one of them corner the market? Will immunotherapy combinations threaten their market share? Is there still hope for Opdivo in the first-line setting?
Takeda confirmed that it plans to shutter operations at its Cambridge Science Park facility in the UK, Business Weekly reported Friday. However, the drugmaker denied reports that it plans to completely... Read More >>